The European pharmaceutical market is evolving rapidly, and companies must adapt. The opportunity to reach all European Union patients is significant. But, failing to address it could mean reduced periods of exclusivity. https://ow.ly/lpLe50Q1ve1 #EuropeanPharma #InnovateInEurope #PharmaStrategies
EVERSANA’s Post
More Relevant Posts
-
Yesterday, Medichem participated in the final Medicines for Europe board meeting of 2023 in Brussels. In 2024, the industry confronts challenges demanding urgent attention. Key priorities include establishing robust EU pharma legislation that prioritizes #accessibility, #affordability, and #availability of medicines. Improving patient access involves streamlining regulatory processes and leveraging technology to minimize delays. Additionally, reducing the environmental impact of the pharmaceutical sector is imperative, requiring sustainable practices. Let's approach these challenges as opportunities for positive transformation, working collectively to align practices with #sustainability principles in the journey ahead.
-
-
Access to prescription treatments for many common ailments and chronic conditions will be expanded if the FDA's "ACNU" Rule is finalized as expected in April. The rule will make it easier for individuals to obtain prescription-strength treatments for many ailments without a doctor's prescription. This is a big deal for individuals who don't have convenient access to a prescribing physician. #FDA #healthcareaccessibility #prescriptiondrugs #ACNU
FDA Releases Fall Unified Agenda; Regulatory Update Impacting Access to Nonprescription Treatments The FDA has recently released its Fall 2023 Unified Regulatory Agenda. There is an important update for professionals and stakeholders in the pharma and consumer healthcare industries. The Additional Conditions for Nonprescription Use (ACNU) rule is expected to be finalized in April next year, which is eagerly awaited. This development marks a significant advancement in the regulatory landscape and has the potential to affect how many nonprescription drugs are managed and accessed. Biograph works across the pharmaceutical and consumer healthcare sectors to leverage innovation to unlock new sources of growth and improve access. We aim to be recognized by the industry and FDA as the premier hub for digital labeling solutions. Our passion is empowering consumers with the capabilities to make healthy decisions. #HealthcareRegulation #FDA #ACNURule #HealthcareNews
-
-
🌟 Important Update 🌟 Yesterday, the U.S. Senate passed a critical provision of the bipartisan Affordable Prescriptions for Patients Act, a victory for increased competition and lower pharmaceutical prices. Authored by Senators John Cornyn (R-TX) and Richard Blumenthal (D-CT), this legislation targets "patent thickets" that hinder competition and inflate costs. The Public Sector HealthCare Roundtable has long championed these reforms and applauds the bipartisan effort to pass this key provision. This is a significant step toward ending anti-competitive practices and passing drug savings along to public sector purchasers. Visit our website to learn more https://lnkd.in/ed_Nsr9T #Healthcare #AffordablePrescriptions #BipartisanSupport #PublicSector
-
-
BRIDGING THE GAP: Challenges remain, including ethical considerations, regulatory hurdles, and ensuring sustainable post-trial access to medicines for participants. However, collaborative efforts between governments, Big Pharma, and local communities can address these concerns and create a win-win situation for all. By increasing clinical trial participation in Africa, we can unlock a future where cutting-edge medical advancements benefit both the continent and the global pharmaceutical industry. It’s time to turn this potential into reality, paving the way for a healthier and more equitable future for all. #ClinicalTrialsForAll #ParticipantCube
-
-
FDA Releases Fall Unified Agenda; Regulatory Update Impacting Access to Nonprescription Treatments The FDA has recently released its Fall 2023 Unified Regulatory Agenda. There is an important update for professionals and stakeholders in the pharma and consumer healthcare industries. The Additional Conditions for Nonprescription Use (ACNU) rule is expected to be finalized in April next year, which is eagerly awaited. This development marks a significant advancement in the regulatory landscape and has the potential to affect how many nonprescription drugs are managed and accessed. Biograph works across the pharmaceutical and consumer healthcare sectors to leverage innovation to unlock new sources of growth and improve access. We aim to be recognized by the industry and FDA as the premier hub for digital labeling solutions. Our passion is empowering consumers with the capabilities to make healthy decisions. #HealthcareRegulation #FDA #ACNURule #HealthcareNews
-
-
Access to prescription treatments for many common ailments and chronic conditions will be expanded if the FDA's "ACNU" Rule is finalized as expected in April. The rule will make it easier for individuals to obtain prescription-strength treatments for many ailments without a doctor's prescription. This is a big deal for individuals who don't have convenient access to a prescribing physician. #FDA #healthcareaccessibility #prescriptiondrugs #ACNU
FDA Releases Fall Unified Agenda; Regulatory Update Impacting Access to Nonprescription Treatments The FDA has recently released its Fall 2023 Unified Regulatory Agenda. There is an important update for professionals and stakeholders in the pharma and consumer healthcare industries. The Additional Conditions for Nonprescription Use (ACNU) rule is expected to be finalized in April next year, which is eagerly awaited. This development marks a significant advancement in the regulatory landscape and has the potential to affect how many nonprescription drugs are managed and accessed. Biograph works across the pharmaceutical and consumer healthcare sectors to leverage innovation to unlock new sources of growth and improve access. We aim to be recognized by the industry and FDA as the premier hub for digital labeling solutions. Our passion is empowering consumers with the capabilities to make healthy decisions. #HealthcareRegulation #FDA #ACNURule #HealthcareNews
-
-
Stand Up Against Big Pharma's Greed: Join Our Digital Day of Action! 📅 Date: June 27th 💻 Where: P4AD Facebook Live 📢 Event: Panel Discussion on Defending Medicare Negotiation and Big Pharma's Lawsuits to Block the Critical Program 🔗 RSVP: https://lnkd.in/e7mYPPrP Big Pharma has filed 9 lawsuits to block Medicare from negotiating lower drug prices. Their greed has forced many patients to ration their medications or skip treatments because of the outrageous costs of their medications. Join us on June 27th for a virtual panel discussion where experts will highlight the critical need for Medicare negotiation. We aim to gather 250,000 signatures demanding that pharmaceutical CEOs #DropTheSuits and prioritize patients over profits. #FightPharma
-
-
Navigating ARTG Variations: Essential Updates for Medical Device Sponsors Published by: TGA in #Australia ; 06-AUG-2024 🚦 Importance: Keeping ARTG entries accurate and up-to-date is critical for maintaining public health, regulatory compliance, and transparency within the pharmaceutical industry. 💡 Insights: This guidance offers clear, actionable steps for sponsors to ensure their ARTG entries reflect the latest, most accurate information, supporting both regulatory obligations and healthcare outcomes. #MedicalDevices #RegulatoryAffairs #HealthcareCompliance #ARTG #Vizenlifesciences
-
Director at PharmOut | FANZCAP (Medsafety, PublicHlth) | Medicine and Medical Device | Clinical Trials | Risk Management | Auditor 9001 & 42001
Title: Navigating ARTG Variations: Essential Updates for Medical Device Sponsors Published by: TGA in #Australia ; 06-AUG-2024 🚦 Importance: Keeping ARTG entries accurate and up-to-date is critical for maintaining public health, regulatory compliance, and transparency within the pharmaceutical industry. 💡 Insights: This guidance offers clear, actionable steps for sponsors to ensure their ARTG entries reflect the latest, most accurate information, supporting both regulatory obligations and healthcare outcomes. #MedicalDevices #RegulatoryAffairs #HealthcareCompliance #ARTG #pharmout PharmOut
-
Stand Up Against Big Pharma's Greed: Join Our Digital Day of Action! 📅 Date: June 27th 💻 Where: P4AD Facebook Live 📢 Event: Panel Discussion on Defending Medicare Negotiation and Big Pharma's Lawsuits to Block the Critical Program 🔗 RSVP: https://lnkd.in/e7mYPPrP Big Pharma has filed 9 lawsuits to block Medicare from negotiating lower drug prices. Their greed has forced many patients to ration their medications or skip treatments because of the outrageous costs of their medications. Join us on June 27th for a virtual panel discussion where experts will highlight the critical need for Medicare negotiation. We aim to gather 250,000 signatures demanding that pharmaceutical CEOs #DropTheSuits and prioritize patients over profits. #FightPharma
-
